Medical Licensing (MD/DO) · Independent exam preparation
Advanced Heart Failure and Transplant Cardiology Certification Examination: Free Preparation Guide Study Guide
Practise advanced HF treatment, shock support, transplant assessment and pulmonary hemodynamics with 60 focused concepts, clinical questions and recall cards.
By CertMedbry · Updated 18 October 2026
Practise choosing heart failure therapy, interpreting invasive hemodynamics, troubleshooting circulatory support and distinguishing transplant complications. This selective guide follows the January 2026 ABIM Certification Examination blueprint, applicable beginning with Fall 2026. Its 60 concepts include 24 Heart Failure, 18 Mechanical Circulatory Support, 15 Heart Transplantation and 3 Pulmonary Hypertension topics. The official expanded outline defines the full scope, including topics beyond this selection.
Try 20 free practice questionsWhat is the exam format?
Check the question types, timing and outline before planning your revision.
Which certification examination does this guide address?
The American Board of Internal Medicine Advanced Heart Failure and Transplant Cardiology Certification Examination. Prior ABIM certification in cardiovascular disease is an eligibility requirement. The workbook label is shorthand for this physician subspecialty examination; it does not identify a separate examination or an initial medical licensure examination.
ABIM: Advanced Heart Failure and Transplant Cardiology Certification Policies
Which blueprint edition applies, and how does CERT differ from maintenance pathways?
This guide uses the January 2026 CERT blueprint and its expanded outline, applicable beginning with the Fall 2026 Certification Examination. ABIM's rollout table also lists Fall 2026 implementation for traditional 10-year MOC and July 2026 implementation for the Longitudinal Knowledge Assessment. These maintenance pathways have separate assessment arrangements; this guide selects CERT.
Advanced Heart Failure and Transplant Cardiology Certification Examination Blueprint — January 2026 · ABIM Expanded Blueprints
What are the official content and physician-task targets?
Content targets are Heart Failure 40%, Mechanical Circulatory Support 30%, Heart Transplantation 25% and Pulmonary Hypertension 5%. Physician-task targets are diagnosis/testing 30%, treatment/care decisions 50%, risk assessment/prognosis/epidemiology 10% and pathophysiology/basic science 10%. Clinically relevant health equity content spans categories. Both 20-item learning sets use an 8/6/5/1 domain allocation.
Advanced Heart Failure and Transplant Cardiology Certification Examination Blueprint — January 2026
How is the examination delivered, and what do questions look like?
The examination is administered in a testing center using single-best-answer multiple-choice questions. Most present clinical scenarios; some require interpretation of images, tracings, tables or other clinical material. ABIM provides a preparation tutorial through its [current CERT examination page](https://www.abim.org/certification/becoming-certified-in-a-subspecialty/register-prepare-for-and-take-your-exam/advanced-heart-failure-and-transplant-cardiology/).
Advanced Heart Failure and Transplant Cardiology Certification Examination Blueprint — January 2026
How many questions are presented, and are all scored?
ABIM describes four sessions containing up to 60 questions each, for a maximum of 240. Its current examination page does not specify a scored/pretest split; do not assume every presented question contributes to the score. See the [current CERT examination page](https://www.abim.org/certification/becoming-certified-in-a-subspecialty/register-prepare-for-and-take-your-exam/advanced-heart-failure-and-transplant-cardiology/).
Advanced Heart Failure and Transplant Cardiology Certification Examination Blueprint — January 2026
How long is the examination, and how are breaks and scoring organized?
ABIM currently describes approximately 10 hours, with four sessions of up to two hours each and 100 total break minutes shared across three breaks. The passing decision uses an absolute standard based on overall examination performance; unanswered questions count as incorrect. See the [current CERT examination page](https://www.abim.org/certification/becoming-certified-in-a-subspecialty/register-prepare-for-and-take-your-exam/advanced-heart-failure-and-transplant-cardiology/).
Advanced Heart Failure and Transplant Cardiology Certification Examination Blueprint — January 2026
Does this guide cover the entire official outline?
No. The 60 concepts selectively sample all four official domains in proportion to their published weights. The official expanded CERT blueprint remains the full scope, including additional etiologies, device configurations, transplant selection issues, donor assessment and longitudinal complications. Use its numbered subtopics to identify remaining study needs.
Advanced Heart Failure and Transplant Cardiology Certification Examination Expanded Blueprint
This is independent preparation for ABIM physician subspecialty certification in Advanced Heart Failure and Transplant Cardiology. The questions and flashcards are original educational materials, without ABIM endorsement or pass prediction.
Outline used: January 2026 ABIM certification blueprint, applicable beginning with the Fall 2026 Certification Examination, with its current expanded content outline. The workbook label 'ABIM - Subspecialty in Advanced Heart Failure and Transplant Cardiology' maps to this official examination; it is not a separate examination. Assigned canonical slug preserved. Verified as of 2026-10-09.
60 key concepts: understand, apply and avoid the traps
Work through the questions by exam domain. Explain the answer in your own words, try the example, then check the common pitfall.
Heart Failure40%
1.How do HF stages change preventive and therapeutic decisions?
HF stage describes disease progression, whereas ejection fraction describes ventricular phenotype. Stage A identifies risk without symptoms or structural disease. Stage B identifies structural disease, elevated filling pressures or qualifying biomarkers without current or previous HF symptoms. Stage C includes current or previous HF symptoms, even after improvement. Stage D involves advanced symptoms that interfere with daily life and recurrent hospitalizations despite treatment efforts. Stage B requires active prevention: eligible patients with LVEF ≤40% should receive an ACE inhibitor and an evidence-based beta-blocker to prevent symptomatic HF. Patients with previous myocardial infarction should also receive statin therapy to prevent adverse cardiovascular events.
Apply it
A stable patient with post-infarction LVEF 34% has never experienced HF symptoms. Classify the patient as Stage B and prescribe an ACE inhibitor, an evidence-based beta-blocker and statin therapy, considering contraindications and tolerability. Check blood pressure, kidney function and potassium when initiating and titrating the ACE inhibitor; assess heart rate and conduction before beta-blocker treatment. Do not wait for edema or exertional dyspnea to begin prevention.
Common pitfall: A low EF alone does not establish Stage C; symptom history distinguishes Stage B from Stage C. Conversely, symptom resolution does not return previously symptomatic HF to Stage B or justify withdrawing protective therapy. Routine loop diuresis addresses congestion and does not replace preventive treatment in an asymptomatic, euvolemic patient.
2.Which four medication classes form foundational HFrEF therapy?
Foundational HFrEF therapy combines renin-angiotensin system treatment, preferably an ARNI when appropriate, an evidence-based beta-blocker, an MRA and an SGLT2 inhibitor. These treatments address complementary pathways and improve clinical outcomes beyond symptom relief. Eligible patients generally benefit from establishing all four classes promptly at tolerated doses, rather than completing titration of one before considering another. Loop diuretics relieve congestion but do not replace this disease-modifying treatment structure.
Apply it
A compensated patient with EF 28% takes only an ARNI and loop diuretic. Review heart rate, blood pressure, renal function and potassium to establish the other eligible foundational classes before concentrating solely on ARNI titration.
Common pitfall: A patient who feels better after diuresis may still lack protective therapy. Symptom control alone does not demonstrate that HFrEF treatment is adequately established.
2024 ACC Expert Consensus for Treatment of HFrEF: Key Points
3.When should an evidence-based beta-blocker be initiated?
Beta-blockers improve chronic HFrEF outcomes by attenuating sustained adrenergic activation, but their immediate negative inotropic effect matters during instability. Initiation or upward titration should wait until HF is compensated and perfusion is adequate. Bisoprolol, carvedilol and sustained-release metoprolol succinate have established HFrEF outcome evidence. Distinguish starting treatment during active shock from continuing a previously tolerated regimen during a stable hospitalization; these are different clinical decisions requiring assessment of hemodynamics.
Apply it
A patient with newly diagnosed HFrEF remains cool, oliguric and dependent on an inotrope. Stabilize perfusion and congestion first. Reconsider beta-blocker initiation after compensation, rather than treating sinus tachycardia as an isolated indication for immediate blockade.
Common pitfall: Tachycardia during low output may be compensatory. Suppressing it before stabilization can worsen perfusion even though beta-blockade is beneficial later in chronic HFrEF.
2024 ACC Expert Consensus for Treatment of HFrEF: Key Points · 2022 AHA/ACC/HFSA Heart Failure Guideline Slide Set
4.Why is an ACE inhibitor washout required before an ARNI?
ACE inhibition and neprilysin inhibition both impair degradation of vasoactive peptides, including bradykinin. Their overlap increases angioedema risk. Sacubitril/valsartan must therefore not be administered with an ACE inhibitor or within 36 hours after its last dose. Confirm the actual final dose rather than relying on a medication-list discontinuation date. A history of angioedema is also a contraindication to ARNI therapy under the cited HF guideline, regardless of the washout interval.
Apply it
A patient took lisinopril at 08:00 on Monday and is otherwise suitable for sacubitril/valsartan. The earliest permissible start is 20:00 Tuesday, provided clinical reassessment identifies no other contraindication to the proposed treatment.
Common pitfall: An ARNI already contains valsartan. Adding an ACE inhibitor for additional neurohormonal blockade introduces harm rather than improving the completeness of foundational therapy.
5.Which renal and potassium criteria support an MRA in HFrEF?
Spironolactone or eplerenone reduces morbidity and mortality in symptomatic HFrEF when kidney function and potassium permit treatment. The cited guideline specifies eGFR greater than 30 mL/min/1.73 m² and potassium below 5.0 mEq/L for initiation. Aldosterone blockade reduces potassium excretion, so eligibility must be followed by ongoing potassium and renal monitoring. Persistent inability to maintain potassium below 5.5 mEq/L requires discontinuation under that guideline rather than unmonitored continuation.
Apply it
Two patients have symptomatic HFrEF. One has eGFR 48 and potassium 4.4; the other has eGFR 25 and potassium 5.2. The first meets initiation criteria, while the second needs correction and reassessment of safety barriers.
Common pitfall: A normal creatinine value alone can conceal reduced filtration. Use estimated GFR and potassium together, and reassess both after starting or changing therapy.
6.Why should HFrEF therapy continue after EF improves?
HF with improved EF describes a previous EF of 40% or less followed by a measurement above 40%. Reverse remodeling can reflect successful suppression of disease mechanisms rather than permanent elimination of the underlying cardiomyopathy. The cited guideline recommends continued HFrEF therapy to prevent relapse, including when patients become asymptomatic. Diuretic requirements may change with volume status, but that symptom-directed adjustment is separate from withdrawing treatments responsible for maintaining myocardial recovery.
Apply it
A patient whose EF rose from 26% to 54% asks to stop all HF medication because exercise tolerance is normal. Explain remission and relapse risk, continue tolerated disease-modifying therapy, and adjust diuretics only according to congestion.
Common pitfall: A preserved EF after treatment does not automatically establish de novo HFpEF. The historical EF trajectory determines the improved-EF phenotype and the need for ongoing therapy.
7.How should creatinine changes be interpreted during decongestion?
Renal function during acute HF reflects perfusion, venous congestion, medication effects and changes in filtration. A modest creatinine increase during effective diuresis does not by itself prove harmful kidney injury or require stopping decongestion. Interpret the trend alongside blood pressure, urine output, symptoms, examination and electrolytes. Persistent congestion with adequate perfusion often supports continued treatment, whereas hypotension, oliguria or progressive biochemical deterioration demands reassessment of volume status and hemodynamic support.
Apply it
After intravenous diuresis, a patient breathes more easily but still has elevated jugular venous pressure. Creatinine increases slightly, blood pressure remains stable and urine output is brisk. Continue monitored decongestion rather than stopping treatment solely because of creatinine.
Common pitfall: Treating every creatinine rise as overdiuresis can leave clinically important congestion untreated. The opposite error is ignoring hypotension or oliguria while pursuing a weight target.
2022 AHA/ACC/HFSA Heart Failure Guideline Slide Set · 2024 ACC Expert Consensus for Treatment of HFrEF: Key Points
8.How do congestion and perfusion define an acute HF profile?
Congestion and perfusion are separate axes of bedside assessment. Elevated jugular venous pressure, pulmonary edema and peripheral edema suggest increased filling pressures; cool extremities, altered mentation and oliguria suggest inadequate tissue perfusion. A patient can be congested with preserved perfusion or congested with low output. This distinction changes the urgency of hemodynamic assessment and support. Blood pressure alone is insufficient because compensatory vasoconstriction can preserve pressure despite reduced forward flow.
Apply it
A patient has pulmonary edema, cool hands, confusion and falling urine output despite a systolic pressure of 105 mmHg. Recognize congestion with hypoperfusion and assess shock physiology instead of classifying the episode as uncomplicated fluid overload.
Common pitfall: A reassuring cuff pressure does not exclude cardiogenic shock. Conversely, edema alone does not establish low output or justify inotropic treatment without evidence of hypoperfusion.
2022 AHA/ACC/HFSA Heart Failure Guideline Slide Set · ACC: 2025 Clinical Guidance on Evaluation and Management of Cardiogenic Shock
9.When does an inadequate diuretic response justify treatment intensification?
Intravenous loop diuretics are central to relieving significant fluid overload in hospitalized HF. Assess their effect through urine output, symptoms, examination and laboratory trends rather than assuming that a prescribed dose produced adequate natriuresis. When congestion persists and response is inadequate, intensification can include a higher intravenous loop dose or addition of a second diuretic. Sequential nephron blockade increases electrolyte and renal risks, making reassessment of potassium, sodium, kidney function and perfusion essential.
Apply it
A hospitalized patient remains orthopneic with elevated jugular venous pressure and little urine response after intravenous loop therapy. Confirm administration and reassess perfusion, then intensify diuresis with close electrolyte monitoring rather than repeating an ineffective plan unchanged.
Common pitfall: Adding another diuretic without confirming persistent congestion and hemodynamic tolerance can worsen depletion. A poor response also warrants checking delivery, renal function and the underlying trigger.
10.Which electrical and clinical findings most strongly support CRT?
CRT treats ventricular electrical dyssynchrony rather than low EF alone. A strong guideline-supported profile includes EF 35% or less, sinus rhythm, left bundle branch block, QRS duration at least 150 milliseconds and persistent NYHA II, III or ambulatory IV symptoms despite GDMT. Resynchronization can improve coordinated contraction, symptoms and outcomes. QRS morphology, duration, rhythm and clinical status must be interpreted together; the most compelling evidence cannot be transferred indiscriminately to narrow-QRS disease.
Apply it
A patient remains NYHA III despite GDMT, with EF 29%, sinus rhythm and left bundle branch block measuring 168 milliseconds. Assess CRT candidacy because the conduction pattern provides a treatable mechanism contributing to persistent ventricular dysfunction.
Common pitfall: Severely reduced EF does not establish a CRT indication when QRS is narrow. Mechanical dysfunction and electrical dyssynchrony are related but distinct treatment targets.
11.How does competing mortality influence primary-prevention ICD benefit?
An ICD interrupts lethal ventricular tachyarrhythmias but does not reverse pump failure or other terminal disease. Primary-prevention selection therefore combines ventricular function, symptoms, treatment status and appropriate timing with an expectation of meaningful survival beyond one year. Benefit is greatest when arrhythmic death risk is substantial and competing nonarrhythmic mortality is relatively low. Severe frailty, advanced comorbidity or refractory HF can reduce the value of implantation even when EF meets a numerical criterion.
Apply it
Two patients have similarly reduced EF after appropriate treatment. One is functionally independent; the other has progressive terminal cancer. Discuss competing mortality and goals because identical EF values do not imply identical net benefit from an ICD.
Common pitfall: An ICD is not a treatment for congestion or low cardiac output. Meeting an EF threshold does not override prognosis, timing requirements or patient preferences.
12.When should recurrent HFrEF deterioration trigger advanced referral?
Advanced HF referral should occur when high-risk features emerge despite attempts to optimize treatment, before irreversible end-organ injury narrows options. Recurrent admissions, refractory congestion, worsening functional limitation, low-output episodes and intolerance of previously tolerated therapy can indicate progression. The referral evaluates reversible causes, treatment optimization, transplantation, durable support and goal-concordant palliation. Referral is an assessment process rather than a commitment to implantation or listing, and should not await dependence on emergency temporary support.
Apply it
A patient has three HF admissions, escalating diuretic requirements and worsening renal function that limits therapy. Arrange advanced HF assessment while reviewing reversible triggers, rather than waiting for a fourth admission with shock or irreversible organ failure.
Common pitfall: Referral is often delayed because individual episodes improve with diuresis. The longitudinal pattern may show advanced disease even when the patient temporarily appears compensated.
2024 ACC Expert Consensus for Treatment of HFrEF: Key Points · 2022 AHA/ACC/HFSA Heart Failure Guideline Slide Set
13.How can palliative care and access support improve HF treatment?
Palliative care addresses symptom burden, quality of life, goals and preparedness throughout HF, including alongside life-prolonging therapy. Effective care also identifies why a feasible prescription is not being taken. Cost, language barriers, limited health literacy and regimen complexity require specific interventions such as pharmacist support, assistance programs and teach-back. These measures influence whether treatment can be implemented safely. A shared plan should connect prognosis and patient priorities with realistic medication access and follow-up arrangements.
Apply it
A patient skips an ARNI because of cost and avoids discussing breathlessness for fear that palliation means abandonment. Arrange access assistance, explain concurrent symptom support and use teach-back to establish an affordable treatment and follow-up plan.
Common pitfall: Labeling missed doses as unwillingness can conceal a solvable access barrier. Offering palliative care only after all disease-directed options end also misses earlier benefits.
2024 ACC Expert Consensus for Treatment of HFrEF: Key Points
14.How does H2FPEF make the diagnostic assessment of HFpEF operational?
HFpEF requires symptoms or signs of HF, EF at least 50% and evidence supporting elevated filling pressures. H2FPEF estimates its probability in unexplained dyspnea: BMI above 30 kg/m² contributes 2 points; treatment with at least two antihypertensives, 1; atrial fibrillation, 3; estimated pulmonary artery systolic pressure above 35 mmHg, 1; age above 60 years, 1; and E/e′ above 9, 1. Totals of 0–1 indicate low probability, 2–5 intermediate probability and 6–9 high probability. Intermediate results support exercise assessment when resting evidence is inconclusive. Continue evaluating pulmonary disease, anemia, valve disease and other mimics.
Apply it
A 68-year-old patient has BMI 36 kg/m², takes two antihypertensives, has no AF, estimated pulmonary artery systolic pressure 32 mmHg and E/e′ of 8. The score is 4, an intermediate result supporting further functional assessment rather than a diagnosis based on EF alone.
Common pitfall: A probability score does not identify every cause of dyspnea. Neither preserved EF nor an isolated echocardiographic diastolic abnormality independently establishes symptomatic HFpEF.
2023 ACC Expert Consensus on Management of HFpEF: Key Points · 2022 AHA/ACC/HFSA Heart Failure Guideline Slide Set
15.How should obesity and inconclusive resting tests change the next HFpEF investigation?
Obesity lowers natriuretic peptide concentrations, so a low NT-proBNP cannot reliably exclude HFpEF when the clinical probability remains substantial. Calculate H2FPEF using the clinical and Doppler findings rather than treating the biomarker as decisive. With an intermediate score of 2–5 and persistent unexplained exertional symptoms, use diastolic exercise echocardiography to assess filling-pressure responses; exercise right-heart catheterization can resolve uncertainty when noninvasive findings remain nondiagnostic. HFA-PEFF provides an alternative sequence of pretest assessment, echocardiographic and natriuretic peptide scoring, functional testing and etiologic investigation. The diagnostic target is exertional elevation of cardiac filling pressures.
Apply it
An obese patient has an intermediate H2FPEF score, low NT-proBNP and nondiagnostic resting pressure estimates. Arrange exercise assessment; if stress echocardiography remains equivocal, invasive exercise measurements can determine whether abnormal filling pressures explain the breathlessness.
Common pitfall: Obesity can both cause noncardiac exercise limitation and suppress HF biomarkers. A low biomarker cannot distinguish these mechanisms, and an intermediate score should lead to testing rather than diagnostic closure.
2023 ACC Expert Consensus on Management of HFpEF: Key Points · Management of HFpEF: 2026 ACC Expert Consensus Decision Pathway — Key Takeaways
16.Which disease-modifying treatments and finerenone safety boundaries guide current HFpEF care?
The 2026 ACC pathway emphasizes early SGLT2 inhibitor therapy and consideration of finerenone, a nonsteroidal MRA. Finerenone is labeled for adults with HF and LVEF at least 40%. Measure potassium and eGFR before treatment: initiation is not recommended below eGFR 25 mL/min/1.73 m², and treatment must not begin with potassium above 5.0 mEq/L. Reassess both four weeks after initiation, four weeks after dose adjustment and periodically thereafter. Contraindications include strong CYP3A4 inhibitors, adrenal insufficiency and hypersensitivity to product components; avoid use in severe hepatic impairment. These boundaries differ from spironolactone/eplerenone initiation in HFrEF, which requires eGFR greater than 30 and potassium below 5.0.
Apply it
A patient with confirmed HFpEF has eGFR 28 and potassium 4.8 without a contraindicated interaction. Finerenone may be considered with planned monitoring. Potassium 5.2 would preclude initiation, and eGFR 23 would make initiation not recommended.
Common pitfall: Do not transfer one MRA's eligibility criteria to another. Finerenone still carries hyperkalemia and renal risks, and does not replace diuretics for congestion or comprehensive comorbidity management.
Management of HFpEF: 2026 ACC Expert Consensus Decision Pathway — Key Takeaways · 215341s009lbl.pdf · 2022 AHA/ACC/HFSA Heart Failure Guideline Slide Set
17.How should cardiometabolic phenotype guide HFpEF treatment?
HFpEF commonly involves interacting obesity, hypertension, diabetes and kidney disease rather than a single isolated ventricular abnormality. Treatment should target that combined burden with therapies offering overlapping cardiovascular, renal and metabolic benefits. The 2026 ACC summary supports incretin-based treatment in obesity and selective consideration of ARNI, particularly in women or patients toward the lower preserved-EF range. Beta-blockers need a specific indication. Phenotype-directed care complements confirmed diagnosis and foundational therapy rather than replacing either.
Apply it
A patient with HFpEF, obesity, diabetes and CKD remains limited despite improved congestion. Review weight-directed treatment and therapies with overlapping cardiorenal benefit, instead of increasing the loop diuretic simply because exercise tolerance remains below normal.
Common pitfall: Persistent breathlessness does not always mean excess fluid. Escalating diuretics without assessing obesity, blood pressure, renal disease and conditioning can produce depletion without improving function.
Management of HFpEF: 2026 ACC Expert Consensus Decision Pathway — Key Takeaways
18.When do exercise and pressure monitoring add value in HFpEF?
Structured exercise and sustained weight management improve functional capacity and quality of life in HFpEF. Their value persists after congestion is controlled because exercise limitation also reflects peripheral and cardiometabolic factors. Selected high-risk patients with persistent symptoms or recurrent admissions may benefit from implantable pulmonary artery pressure monitoring. Monitoring is useful only when measurements lead to a reliable treatment response pathway, with education, clinical review and access to medication adjustments rather than passive collection of pressure values.
Apply it
A clinically euvolemic patient remains deconditioned after HFpEF hospitalization. Arrange structured exercise and weight support. If recurrent admissions continue despite comprehensive care, assess whether pressure-guided management can be implemented through an experienced follow-up team.
Common pitfall: An implanted monitor does not treat elevated filling pressures itself. Its usefulness depends on actionable readings, patient participation and a team able to adjust treatment.
Management of HFpEF: 2026 ACC Expert Consensus Decision Pathway — Key Takeaways
19.Why does atrial fibrillation require individualized management in HFpEF?
Atrial fibrillation can worsen HFpEF through loss of coordinated atrial contraction, irregular filling and excessive ventricular rates. Management balances rate control against the risk of excessive slowing and considers rhythm control when symptoms persist. The 2026 ACC summary includes ablation among options for symptomatic patients and limits beta-blockers to specific indications. Establish whether AF is contributing to functional limitation, rather than assuming every symptom reflects congestion or that progressively lower heart rates always improve filling.
Apply it
A patient with HFpEF develops substantial exercise intolerance after persistent AF begins, despite a euvolemic examination. Assess rate behavior and discuss rhythm-control options, rather than repeatedly increasing diuretics in response to the same exertional symptoms.
Common pitfall: Aggressive rate slowing may worsen exertional capacity in some patients. The desired ventricular rate must be judged alongside symptoms, blood pressure and exercise response.
Management of HFpEF: 2026 ACC Expert Consensus Decision Pathway — Key Takeaways
20.Which tests distinguish AL from ATTR cardiac amyloidosis?
Suspected cardiac amyloidosis requires identification of the deposited protein because AL and ATTR have different mechanisms and treatments. Initial monoclonal evaluation includes serum free light chains plus serum and urine immunofixation. If monoclonal testing is abnormal, tissue assessment with definitive amyloid typing is needed; bone-tracer uptake alone cannot safely establish ATTR. After AL has been excluded, appropriate scintigraphy can support ATTR diagnosis. Routine protein electrophoresis alone is insufficiently sensitive for the monoclonal screen.
Apply it
A patient has unexplained wall thickening, apical strain sparing and a positive bone-tracer scan, but serum immunofixation detects a monoclonal protein. Pursue tissue typing rather than treating the scan as definitive evidence of ATTR.
Common pitfall: A monoclonal protein does not itself prove AL deposition, and a positive bone scan does not exclude it. Protein typing resolves this clinically consequential ambiguity.
2023 ACC Expert Consensus on Cardiac Amyloidosis: Key Points
21.Why is genetic testing needed after ATTR is established?
ATTR cardiomyopathy can result from deposition of genetically normal transthyretin or a pathogenic TTR variant. Imaging demonstrates the cardiac phenotype but cannot determine which subtype is present. Genetic testing distinguishes variant from wild-type disease and informs counseling and potential evaluation of relatives. Older age does not exclude hereditary disease. The decision follows reliable amyloid typing, because testing TTR does not replace excluding AL or proving that an uncertain cardiac presentation represents ATTR deposition.
Apply it
An older adult has a confirmed nonbiopsy ATTR diagnosis after appropriate monoclonal exclusion and scintigraphy. Offer TTR genetic testing and counseling even without a known family history, because age and pedigree alone cannot establish wild-type disease.
Common pitfall: Calling ATTR wild type solely because the patient is elderly can miss a heritable variant. A negative family history may reflect incomplete recognition or expression.
2023 ACC Expert Consensus on Cardiac Amyloidosis: Key Points
22.When should cardiomyopathy trigger genetic and family evaluation?
Inherited cardiomyopathy should be considered when ventricular disease coexists with early conduction abnormalities, ventricular arrhythmias, unexplained sudden death or similarly affected relatives. Obtain a three-generation family history, including indirect clues such as early pacemakers, unexplained drowning or presumed premature heart attacks without documented coronary disease. Selected patients benefit from genetic counseling and testing, followed by appropriate family assessment. A genetic diagnosis can clarify surveillance needs even when the index patient's immediate HF treatment remains unchanged.
Apply it
A patient with nonischemic cardiomyopathy reports a sibling with an early pacemaker and a parent who died suddenly while swimming. Obtain a detailed pedigree and arrange genetic counseling rather than assuming the cardiomyopathy is sporadic.
Common pitfall: Absence of a recorded cardiomyopathy diagnosis in relatives does not exclude inheritance. Unexplained arrhythmias, early devices and sudden deaths can be more informative clues.
23.How should an etiologic workup change management of new cardiomyopathy?
Choose investigations according to findings that could change treatment. Angina, coronary risk factors, infarction-pattern ECG changes or regional wall-motion abnormalities support coronary evaluation. Cardiac MRI can distinguish subendocardial or transmural scar in a coronary distribution, suggesting ischemic injury, from nonischemic injury patterns. Myocardial edema with subepicardial enhancement supports an inflammatory process but does not establish its histologic subtype. Endomyocardial biopsy is appropriate when a specific suspected diagnosis would alter treatment, particularly rapidly progressive unexplained dysfunction with shock, ventricular arrhythmias or high-grade conduction disease suggesting an actionable inflammatory cardiomyopathy. Routine biopsy of otherwise stable cardiomyopathy is not recommended. Treat congestion and initiate appropriate HF therapy while investigating the cause.
Apply it
A patient previously treated with doxorubicin develops an LVEF of 30%. Global hypokinesis could fit treatment-related dysfunction, but exertional chest pressure and disproportionate inferior akinesis require coronary evaluation rather than attribution to chemotherapy alone. Coronary angiography demonstrating severe multivessel disease establishes an actionable ischemic contribution and prompts coronary secondary prevention and assessment for appropriate revascularization. If obstructive coronary disease is absent, cardiac MRI can further characterize myocardial injury. Compatible exposure history and otherwise unexplained global dysfunction support treatment-related cardiomyopathy, leading to HF therapy and reassessment of ongoing cardiotoxic treatment with oncology. Conversely, rapid deterioration accompanied by ventricular tachycardia and new high-grade atrioventricular block warrants consideration of biopsy: identifying giant-cell myocarditis would introduce disease-specific immunosuppression and urgent advanced-HF planning.
Common pitfall: Neither chemotherapy exposure nor a nonischemic MRI pattern proves a single cause. Multiple mechanisms can coexist, and absent late gadolinium enhancement does not exclude treatment-related dysfunction. MRI cannot reliably replace tissue diagnosis when identifying a specific inflammatory subtype would change therapy. Reserve biopsy for an actionable diagnostic question rather than performing it routinely because the ejection fraction is reduced.
24.When should persistent tachyarrhythmia be considered a cause of ventricular dysfunction?
Sustained tachyarrhythmia, frequent ventricular ectopy or abnormal pacing activation can contribute to cardiomyopathy rather than merely accompany it. Establish the arrhythmia burden, its temporal relationship to ventricular decline and alternative causes of myocardial disease. Improvement after effective arrhythmia treatment supports a causal contribution, although recovery does not eliminate the need for ongoing HF assessment. A single normal resting heart rate cannot exclude a substantial ambulatory arrhythmia burden or recurrent periods of rapid ventricular response.
Apply it
A patient with newly reduced EF has persistent AF and frequent rapid rates on ambulatory monitoring despite a normal clinic pulse. Treat the arrhythmia and HF together, then reassess ventricular function to evaluate a potentially reversible contribution.
Common pitfall: Assuming every arrhythmia is secondary to structural disease can miss a treatable driver. Improvement after rhythm treatment also does not prove there was no underlying cardiomyopathy.
Mechanical Circulatory Support30%
25.When does cardiogenic shock require early support-center collaboration?
Cardiogenic shock is a dynamic failure of tissue perfusion that can progress despite initially acceptable arterial pressure. Persistent hypoperfusion, worsening organ function or increasing pharmacologic support should prompt early collaboration with a shock-capable center. Temporary support is considered when medications cannot maintain adequate perfusion, using repeated clinical and hemodynamic assessment to match the intervention to the failing circulation. Transfer planning should begin before deterioration makes transport or definitive treatment substantially more difficult.
Apply it
A community hospital patient has rising lactate, oliguria and escalating vasoactive requirements after myocardial injury. Contact a shock center while treating the cause and clarifying hemodynamics, rather than waiting until cardiovascular collapse before discussing transfer.
Common pitfall: A single improved blood pressure after vasopressor escalation does not establish recovery. Perfusion trends, support requirements and the underlying cause determine whether escalation remains necessary.
ACC: 2025 Clinical Guidance on Evaluation and Management of Cardiogenic Shock
26.How do invasive hemodynamics and respiratory function guide selection of temporary mechanical support?
Match device anatomy to the failing circulation. Right atrial drainage with pulmonary artery return bypasses and assists the RV, delivering blood through the lungs to the left heart; adequate LV function is therefore necessary. LV-to-aortic support unloads the LV and supplies systemic flow but depends on adequate RV delivery through the pulmonary circulation. Biventricular failure may require support of both ventricles or VA-ECMO. VA-ECMO drains systemic venous blood, oxygenates it and returns it to the arterial circulation, providing circulatory support and gas exchange. Its arterial return can increase LV afterload, particularly with retrograde femoral flow, causing LV distension and pulmonary edema. Assess aortic valve opening and the need for LV unloading.
Apply it
High right atrial pressure, a dilated dysfunctional RV and relatively modest wedge pressure suggest dominant RV failure: an RA-to-pulmonary-artery configuration directly addresses that anatomy if the LV can accommodate the restored flow. High wedge pressure with predominant LV dysfunction favors LV support. Severe respiratory failure changes the requirement because a ventricular assist pump without an oxygenator does not oxygenate blood. Combined shock and respiratory failure may favor VA-ECMO; selected extracorporeal RV support circuits can incorporate an oxygenator. Isolated respiratory failure with adequate circulation can instead be supported with venovenous ECMO, which does not directly provide systemic circulatory assistance.
Common pitfall: Neither EF nor cardiac output alone identifies the appropriate configuration. Integrate right atrial pressure, wedge pressure, echocardiography, oxygenation and clinical perfusion. Isolated LV support can remain underfilled during severe RV failure; isolated RV support can worsen pulmonary congestion if the LV cannot accept the additional flow. VA-ECMO supplies oxygenated systemic blood but does not guarantee LV decompression.
ACC: 2025 Clinical Guidance on Evaluation and Management of Cardiogenic Shock · ELSO Interim Guidelines for Venoarterial ECMO in Adult Cardiac Patients
27.How should IABP inflation and deflation be timed?
An intra-aortic balloon pump produces counterpulsation by inflating during diastole and deflating immediately before ventricular systole. Inflation begins at the dicrotic notch, augmenting diastolic aortic pressure; presystolic deflation lowers the pressure against which the LV ejects. Timing is judged on the arterial waveform rather than by the largest displayed pressure alone. Early inflation or delayed deflation can oppose ventricular ejection, undermining the intended unloading effect even when a prominent augmented pressure is visible.
Apply it
During IABP review, balloon inflation begins before aortic valve closure and the assisted systolic pressure rises. Reassess timing against the dicrotic notch and presystolic deflation, because apparent augmentation can coexist with an adverse effect on LV ejection.
Common pitfall: Maximizing the augmented peak is not the sole goal. Correct timing must also reduce assisted end-diastolic pressure and avoid increasing the load during systolic ejection.
28.Why can an IABP monitor mislabel the highest arterial pressure?
The highest point on an IABP-supported arterial waveform may be diastolic augmentation rather than native systole. Some bedside monitors identify peaks without recognizing counterpulsation and therefore label the augmented peak as systolic pressure. Interpret assisted systolic, unassisted systolic, augmented diastolic and mean pressures using the waveform and IABP console. Confirm signal quality and the intended hemodynamic target before changing vasoactive treatment in response to an apparently discrepant cuff or bedside-monitor value.
Apply it
The bedside monitor reports systolic pressure 128 mmHg, but the IABP console shows native systole 92 mmHg and augmented diastole 128 mmHg. Identify the augmented peak correctly and use verified waveform data for the prescribed treatment target.
Common pitfall: An impressive displayed systolic value can actually represent diastolic augmentation. Treating that number as native systolic pressure can lead to inappropriate reduction of needed support.
29.Which anatomy makes transvalvular Impella placement unsuitable?
A left-sided transvalvular Impella draws blood from the LV and ejects it into the aorta across the aortic valve. That path makes valve and ventricular anatomy central to safe selection. The cited Impella 2.5 labeling lists a mechanical aortic valve and LV mural thrombus among contraindications; significant aortic valve disease and unsuitable arterial access also matter. Preplacement imaging assesses the proposed route and embolic hazards. Historical device labeling should not be generalized into current indications for every model.
Apply it
A patient needing temporary LV support has a mechanical aortic valve. Exclude the cited transvalvular Impella option and discuss an alternative support strategy with the shock team after assessing respiratory needs, vascular access and biventricular function.
Common pitfall: Adequate femoral access does not establish device suitability. A contraindication along the intracardiac path remains decisive even when the arterial insertion route is technically accessible.
Impella 2.5 Instructions for Use and Clinical Reference Manual
30.How should an Impella suction alarm be investigated?
A suction alarm indicates that inflow conditions are inadequate for the current pumping demand, often because the LV is underfilled or the inlet is malpositioned. Potential causes include hypovolemia, RV failure and contact with ventricular structures. Assess hemodynamics, echocardiographic position and volume status while promptly managing the alarm according to device procedures. Increasing speed without correcting inflow can worsen suction. Fluid is appropriate only when the overall assessment supports insufficient circulating volume rather than congested RV failure.
Apply it
An Impella patient develops suction alarms with high venous pressure and a dilated failing RV. Evaluate position and support RV output; avoid assuming that every underfilled LV requires a large fluid bolus despite systemic venous congestion.
Common pitfall: Low device flow does not automatically mean insufficient pump speed. A pump cannot provide sustained forward flow when its inlet lacks adequate blood or is malpositioned.
Impella 2.5 Instructions for Use and Clinical Reference Manual
31.Why can peripheral VA-ECMO cause LV distension?
Peripheral VA-ECMO returns blood into the arterial system and can increase aortic afterload. A severely impaired LV may then fail to open the aortic valve while residual pulmonary and bronchial flow continues filling the left heart. Consequences include LV distension, pulmonary edema and blood stasis. Poor pulsatility, persistent valve closure and echocardiographic spontaneous contrast are warning signs. These findings require prompt assessment of unloading strategies while preserving systemic perfusion; greater circuit flow is not automatically corrective.
Apply it
After femoral VA-ECMO initiation, systemic pressure improves but pulmonary edema worsens and the aortic valve remains closed. Recognize LV loading and discuss unloading, rather than interpreting the higher arterial pressure as complete hemodynamic success.
Common pitfall: Systemic circulatory support does not guarantee LV decompression. Increasing ECMO flow can improve arterial pressure while further increasing the load faced by a failing ventricle.
ELSO Interim Guidelines for Venoarterial ECMO in Adult Cardiac Patients
32.How does differential hypoxemia develop during femoral VA-ECMO?
When native LV ejection recovers before lung gas exchange, poorly oxygenated pulmonary venous blood can supply the proximal aorta while oxygenated femoral ECMO return supplies the lower body. This creates differential hypoxemia and threatens cerebral and coronary oxygen delivery despite reassuring lower-body oxygenation. Right upper-extremity pulse oximetry and right radial arterial blood gases help detect the problem. Management reassesses lung function, native output and circuit configuration rather than relying solely on postoxygenator or femoral blood gases.
Apply it
A patient on femoral VA-ECMO has excellent femoral oxygenation but a low right radial PaO2 as pulsatility returns. Evaluate differential oxygenation and pulmonary function, and discuss circuit changes if upper-body hypoxemia persists despite appropriate respiratory management.
Common pitfall: A normal postoxygenator blood gas confirms oxygenator performance, not oxygen delivery to every arterial territory. Sampling location becomes decisive when native and circuit flows compete.
ELSO Interim Guidelines for Venoarterial ECMO in Adult Cardiac Patients
33.Why does femoral VA-ECMO require dedicated limb-perfusion surveillance?
A large femoral arterial cannula can compromise distal limb blood flow through obstruction, vascular injury or thrombosis. Systemic pressure and satisfactory circuit flow do not exclude local ischemia. Assess temperature, color, Doppler flow and other available perfusion measures repeatedly, with attention to distal perfusion access and its patency. New limb findings require urgent vascular assessment. Prevention and monitoring are part of support management because delayed recognition can lead to tissue injury despite successful central hemodynamic stabilization.
Apply it
A VA-ECMO patient's cannulated foot becomes cooler with declining Doppler signals while lactate and systemic pressure improve. Urgently assess distal perfusion and vascular complications rather than attributing the local change to generalized shock that is already resolving.
Common pitfall: Global perfusion markers can improve while one limb becomes ischemic. A distal perfusion catheter also requires surveillance because its presence does not guarantee ongoing patency.
ELSO Interim Guidelines for Venoarterial ECMO in Adult Cardiac Patients
34.How is readiness for VA-ECMO liberation assessed?
VA-ECMO liberation requires evidence that the native circulation can sustain perfusion as extracorporeal assistance decreases. Use a supervised reduction in support with serial blood pressure, perfusion and echocardiographic assessment of both ventricles and valve function. Apparent recovery at full flow may conceal inadequate RV or LV reserve because loading conditions are altered. Evaluate respiratory recovery as well. Low-flow trials require attention to circuit thrombosis risk and anticoagulation; a single improved EF is insufficient evidence for safe decannulation.
Apply it
A recovering patient has better LV contraction at full ECMO flow. During supervised flow reduction, right-sided pressures rise and perfusion falls. Recognize that native biventricular reserve remains inadequate and reassess the recovery or bridge strategy.
Common pitfall: Full-support stability is not equivalent to independence from support. Residual ECMO flow changes preload and afterload and can mask clinically important ventricular dysfunction during assessment.
ELSO Interim Guidelines for Venoarterial ECMO in Adult Cardiac Patients
35.How should a time-limited trial of temporary support be framed?
Temporary mechanical support creates time for recovery, further assessment or transition to another therapy; its purpose should be explicit. A time-limited trial identifies the anticipated bridge, measurable signs of progress and circumstances that require reassessment. Relevant outcomes include organ perfusion, neurologic recovery, myocardial recovery and feasibility of durable therapy or transplantation. Palliative care and shared decision making help align continuing support with the patient's goals. Device availability alone does not establish a beneficial long-term pathway.
Apply it
A patient receives temporary support while neurologic prognosis remains uncertain. Agree with the surrogate on reassessment milestones, including organ recovery and neurologic evaluation, and discuss possible next steps if recovery or an acceptable advanced-therapy pathway does not emerge.
Common pitfall: Beginning support without discussing its intended bridge can create an indefinite treatment trajectory. Reassessment should evaluate patient-centered benefit, rather than circuit function alone over time.
Advanced Heart Failure and Transplant Cardiology Certification Examination Expanded Blueprint · 2024 ACC Expert Consensus for Treatment of HFrEF: Key Points · ACC: 2025 Clinical Guidance on Evaluation and Management of Cardiogenic Shock
36.Which factors determine whether durable LV support is feasible?
Durable LV support assessment integrates advanced HF severity with RV function, end-organ disease, comorbidities and the practical ability to manage the system. The device requires reliable power, driveline care, medication management and rapid response to alarms. Assess health literacy, caregiver arrangements and access barriers so that remediable problems can be addressed. A low EF establishes neither sufficient disease severity nor acceptable overall risk. Evaluation also clarifies whether the intended pathway is transplantation, long-term support or another goal.
Apply it
A patient with recurrent low-output admissions is interested in durable support but lacks secure electricity at home. Continue clinical assessment while arranging practical power and support resources, rather than ignoring the barrier or treating it as automatically irreversible.
Common pitfall: Technical implantability is only one part of suitability. Treating social barriers as fixed patient traits can also overlook resources that make safe treatment feasible.
Advanced Heart Failure and Transplant Cardiology Certification Examination Expanded Blueprint · HeartMate 3 Left Ventricular Assist System Instructions for Use
37.Why can RV failure produce low flow after LVAD implantation?
An LVAD depends on the RV to deliver blood through the pulmonary circulation into its LV inlet. RV failure can therefore cause systemic venous congestion and inadequate LVAD filling simultaneously. High right-sided pressure, RV dilation and low device flow support this mechanism. Management addresses RV contractility, pulmonary vascular load, rhythm and appropriate fluid balance; selected severe cases require right-sided support. Increasing LVAD speed cannot replace deficient RV delivery and may aggravate ventricular underfilling or suction.
Apply it
Soon after LVAD implantation, a patient develops elevated jugular venous pressure, a dilated poorly contracting RV and low pump flow. Evaluate postoperative RV failure and its triggers instead of reflexively increasing pump speed or giving unrestricted fluid.
Common pitfall: An underfilled LV does not always indicate whole-body volume depletion. Venous congestion with poor RV forward flow can coexist with inadequate blood reaching the pump.
HeartMate 3 Left Ventricular Assist System Instructions for Use
38.How does hypovolemia differ from congested RV failure in an LVAD patient?
Both hypovolemia and RV failure can reduce LVAD inflow, but the surrounding physiology differs. Hypovolemia is suggested by fluid loss, low filling pressures and absence of congestion; RV failure is suggested by elevated venous pressure and impaired RV function. Integrate examination, recent intake and losses, laboratory trends and echocardiography before choosing fluid or decongestive treatment. Device flow is a consequence of filling conditions and cannot independently identify whether a patient needs additional volume or removal of excess volume.
Apply it
An LVAD patient develops low-flow alarms after several days of vomiting. The examination shows low venous pressure and no edema. Evaluate and correct volume depletion while checking for other causes, rather than assuming every low-flow episode is RV failure.
Common pitfall: Identical alarms can arise from opposite volume states. Treating the alarm label without examining filling pressures and the clinical history can worsen the underlying problem.
HeartMate 3 Left Ventricular Assist System Instructions for Use
39.How can arrhythmia or tamponade reduce LVAD output?
A functioning LVAD still requires adequate cardiac filling. Arrhythmias can impair RV delivery and ventricular coordination, while tamponade restricts filling through external compression. Either can lower device flow without primary pump failure. New low-flow alarms with hemodynamic deterioration require simultaneous assessment of rhythm, perfusion, volume status and echocardiography. In a recently operated patient, bleeding or pericardial compression deserves particular attention. A normal power connection establishes only part of system integrity, not adequate cardiovascular conditions for pump output.
Apply it
A recently implanted LVAD patient abruptly becomes hypotensive with low flow and rising venous pressure. Obtain urgent rhythm and echocardiographic assessment, including evaluation for tamponade, while checking the system rather than treating the event as simple dehydration.
Common pitfall: A pump can be electrically functional while circulation fails from impaired filling. Repeated fluid administration without investigating acute obstruction or arrhythmia can delay definitive treatment.
HeartMate 3 Left Ventricular Assist System Instructions for Use
40.Why are driveline stabilization and exit-site assessment essential?
The driveline creates a persistent passage through the skin and a potential route for infection. Traction and repeated movement can damage the exit site and undermine its protective barrier. Use the implanting center's dressing and stabilization approach, keep the site protected and examine new drainage, erythema, tenderness or systemic symptoms promptly. Superficial appearance alone cannot determine infection depth. Patient education should connect daily care and securement with early reporting rather than relying only on scheduled clinic inspection.
Apply it
An LVAD patient reports new drainage after the driveline repeatedly caught on clothing. Arrange prompt exit-site and systemic assessment, review stabilization and obtain appropriate diagnostic evaluation rather than advising the patient to cover the drainage until routine follow-up.
Common pitfall: Absence of fever does not exclude a driveline problem. Treating visible drainage as a dressing issue alone may miss infection or deeper tissue involvement.
HeartMate 3 Left Ventricular Assist System Instructions for Use
41.How should continuous LVAD power be protected during daily transitions?
A durable LVAD requires uninterrupted electrical power. Power-source transitions must preserve a functioning connection, following the model-specific instructions, rather than disconnecting both sources together. Patients and caregivers need practical rehearsal, charged backup batteries and ready access to emergency equipment and contact information. Alarm response should distinguish a supply problem from other causes of low flow, while maintaining circulation. Competence is demonstrated by performing the transition safely, not simply by repeating that batteries should be kept charged.
Apply it
During discharge teaching, a caregiver plans to remove both depleted batteries before attaching replacements. Stop the practice and rehearse the approved sequential change so that the pump remains powered throughout the transition between available energy sources.
Common pitfall: Two replacement batteries nearby do not protect a pump during simultaneous disconnection. The critical issue is uninterrupted connection, together with model-specific alarm and backup procedures.
HeartMate 3 Left Ventricular Assist System Instructions for Use
42.When should anemia or neurologic symptoms change LVAD assessment?
Bleeding, thromboembolic events and neurologic complications remain important hazards during durable support. New anemia, gastrointestinal bleeding, focal weakness or altered consciousness requires prompt evaluation even when device flow appears satisfactory. A normal controller display cannot exclude systemic complications. Assess perfusion and the relevant clinical syndrome while involving the support team; treatment decisions must account for competing bleeding and thrombotic risks. Do not attribute fatigue or confusion automatically to chronic HF without investigating an acute complication.
Apply it
An LVAD patient with unchanged controller readings develops melena, dizziness and falling hemoglobin. Arrange urgent bleeding and hemodynamic assessment with the LVAD team instead of reassuring the patient that normal device parameters exclude a serious support-related problem.
Common pitfall: Controller stability is not a screen for stroke or bleeding. Independently changing antithrombotic treatment without assessing both hazards can introduce a second serious complication.
HeartMate 3 Left Ventricular Assist System Instructions for Use
Heart Transplantation25%
43.How does transplant evaluation distinguish reversible from persistent organ dysfunction?
Advanced HF can impair kidney and liver function through low output and venous congestion, but candidates may also have intrinsic irreversible organ disease. Transplant assessment examines the trajectory, response to hemodynamic optimization and evidence of underlying pathology rather than treating one abnormal laboratory value as definitive. This distinction influences the anticipated benefit and feasibility of isolated heart transplantation and whether combined-organ assessment is relevant. Early referral provides time for clarification before acute deterioration obscures the baseline condition.
Apply it
A transplant referral has impaired kidney function during severe congestion that improves after stabilization. Review prior renal trends and evidence of intrinsic disease before deciding whether dysfunction is predominantly hemodynamic or requires a combined-organ assessment.
Common pitfall: One creatinine measured during decompensation cannot establish irreversible kidney disease. Improvement with treatment is informative, but does not exclude coexisting intrinsic pathology requiring further assessment.
Advanced Heart Failure and Transplant Cardiology Certification Examination Expanded Blueprint · 2022 AHA/ACC/HFSA Heart Failure Guideline Slide Set
44.Why does transplant candidacy require repeated assessment while waiting?
Transplant candidacy changes with disease progression, recovery, new infection, organ dysfunction and the ability to sustain treatment. Waiting-list management therefore requires repeated assessment of perfusion, congestion, comorbidities, adherence barriers and support needs. Deterioration may prompt bridge-therapy evaluation, while a new serious complication may alter the immediate risk-benefit balance. The clinical principle is dynamic reassessment; allocation categories and listing rules are separate jurisdiction-specific policies and should not be inferred from general severity markers or an earlier candidacy decision.
Apply it
A previously stable candidate develops recurrent low-output admissions and worsening renal function. Reassess hemodynamics and bridging options promptly while checking for new reversible barriers, rather than assuming that the original evaluation remains sufficient throughout the waiting period.
Common pitfall: Acceptance for transplantation is not a permanent statement of unchanged risk. Equally, greater illness severity does not by itself establish a particular allocation status.
Advanced Heart Failure and Transplant Cardiology Certification Examination Expanded Blueprint · 2024 ACC Expert Consensus for Treatment of HFrEF: Key Points
45.Why does recipient pulmonary vascular load threaten the donor RV?
After heart transplantation, the donor RV must immediately eject into the recipient's pulmonary circulation. Elevated pulmonary vascular load can cause early RV failure, particularly when it persists despite reduction of left-sided filling pressures. Evaluate mean pulmonary artery pressure, wedge pressure, cardiac output and the broader hemodynamic context rather than pulmonary pressure alone. PVR separates a flow-adjusted pressure gradient from passive pressure transmission, while reversibility assessment helps characterize risk. No single universal exclusion threshold is established by the cited observational study.
Apply it
A candidate has mean pulmonary artery pressure 36 mmHg, wedge pressure 24 mmHg and cardiac output 4 L/min. Calculate PVR as 3 Wood units, then interpret the result with congestion, treatment response and the complete transplant risk assessment.
Common pitfall: High pulmonary artery pressure may largely reflect high left atrial pressure. Conversely, persistent vascular load can remain after decongestion and still threaten the donor RV.
Hemodynamic Markers of Pulmonary Vasculopathy for Prediction of Early Right Heart Failure and Mortality After Heart Transplantation · Definition, Classification and Diagnosis of Pulmonary Hypertension — 2024 World Symposium Task Force Report
46.How does donor-specific antibody information affect donor compatibility?
A recipient antibody becomes donor specific when its HLA target is present in the proposed donor. Compatibility assessment therefore requires both recipient antibody characterization and donor typing. A virtual crossmatch compares these data to estimate immunologic risk before transplantation. The result must account for assay interpretation, specimen timing and sensitization history; an isolated numerical antibody signal is not a universal measure of biological risk. Donor assessment integrates this information with the wider clinical evaluation rather than treating donor quality and recipient compatibility as interchangeable.
Apply it
A recipient has antibodies against an HLA antigen carried by one potential donor but absent from another. Recognize that the same recipient antibody profile has different donor-specific implications, and request interpretation with current typing and antibody data.
Common pitfall: An antibody's presence does not make it donor specific for every offer. Conversely, favorable donor ventricular function cannot neutralize clinically relevant recipient-donor immunologic incompatibility.
2025 ISHLT Consensus Summary on Antibodies and Antibody-Mediated Rejection in Heart Transplantation
47.Why can sensitization history make an old virtual crossmatch unreliable?
HLA antibody profiles can change after sensitizing exposures such as transfusion, pregnancy or previous transplantation. A virtual crossmatch depends on the antibody information available at the time it is interpreted. Recent exposures therefore make specimen timing and historical antibody results clinically relevant. Assess current and prior findings together, recognizing that assay signal strength has technical limitations. The purpose is to estimate donor-specific risk accurately, rather than assume that a previously acceptable profile remains valid after a new immune exposure.
Apply it
A waiting candidate receives multiple transfusions after an antibody sample was collected. Before interpreting compatibility with a new donor, notify the histocompatibility team about the exposure and reassess whether updated testing is needed for a reliable current evaluation.
Common pitfall: A negative result from an outdated sample may not represent current sensitization. Numerical assay changes also require interpretation rather than automatic conversion into a universal rejection-risk threshold.
2025 ISHLT Consensus Summary on Antibodies and Antibody-Mediated Rejection in Heart Transplantation
48.How do timing and cause classify early post-transplant graft dysfunction?
ABIM's outline names primary allograft dysfunction. The 2026 ISHLT consensus replaces the previous primary graft dysfunction terminology with early graft dysfunction of unknown cause: EGD occurs before 24 hours, and subsequent early graft dysfunction, sEGD, occurs at 24–72 hours. Dysfunction with an identifiable cause is secondary graft dysfunction; investigate tamponade, surgical complications, hyperacute rejection and recipient pulmonary vascular load. Classify unknown-cause dysfunction as LV/biventricular or isolated RV. Severe EGD-LV has an immediate presentation when the graft cannot be weaned from cardiopulmonary bypass, or a delayed presentation after successful separation. Echocardiography and invasive hemodynamics guide stabilization and mechanical support when needed.
Apply it
A recipient separates successfully from bypass but develops severe biventricular dysfunction six hours later. After excluding secondary causes, classify this as EGD with delayed presentation. Similar unknown-cause dysfunction beginning at 36 hours belongs to sEGD.
Common pitfall: Delayed presentation within the first 24 hours is distinct from sEGD at 24–72 hours. Timing alone never excludes a surgically correctable or immunologic secondary cause.
Advanced Heart Failure and Transplant Cardiology Certification Examination Expanded Blueprint · 2026_consensusdocument_ishlt_graftdysfunctionafterhtx.pdf
49.How does tacrolimus suppress rejection, and why are troughs monitored?
Tacrolimus is a calcineurin-inhibitor immunosuppressant that suppresses T-cell activation. Its therapeutic margin is constrained by rejection from inadequate exposure and toxicity from excessive exposure. Whole-blood trough monitoring must therefore be interpreted with dose timing, formulation, adherence, interacting drugs and organ function. A sample taken after the morning dose is not a true predose trough. Immediate-release and extended-release products are not automatically interchangeable, and conversion requires supervised management rather than substitution based only on the drug name.
Apply it
A transplant recipient has an unexpectedly high reported trough but took tacrolimus shortly before blood collection. Verify timing and arrange correctly timed monitoring before interpreting the result as proof that the maintenance dose produces excessive predose exposure.
Common pitfall: A tacrolimus concentration is meaningful only in context. Formulation changes, dosing errors and mistimed samples can mimic pharmacokinetic instability or lead to unsafe dose adjustments.
50.How do CYP3A inhibitors and inducers change tacrolimus exposure?
Tacrolimus exposure is sensitive to CYP3A-mediated interactions. Inhibitors can raise concentrations and increase nephrotoxicity or neurotoxicity, whereas inducers can lower concentrations and compromise rejection protection. Starting, stopping or changing an interacting medication requires planned concentration and clinical monitoring, with dose adjustment as needed. Grapefruit is another relevant exposure. Do not infer the direction of an interaction from the new drug's therapeutic category alone; review its specific metabolic effects and the patient's complete medication history.
Apply it
A recipient starts a CYP3A-inhibiting antifungal and later develops tremor and rising creatinine. Check tacrolimus exposure and coordinate treatment adjustment promptly, rather than attributing both findings solely to progression of unrelated neurologic and renal disease.
Common pitfall: Stopping an inhibitor can also change exposure substantially. Monitoring only when an interacting medication is started misses the rejection risk that can follow its withdrawal.
51.Which findings suggest tacrolimus toxicity after transplantation?
Tacrolimus can cause nephrotoxicity, tremor or other neurotoxicity, hyperkalemia, hypertension and new-onset diabetes. These adverse effects overlap with common post-transplant disorders, so diagnosis requires a concentration trend, medication review and assessment for alternative causes. Renal dysfunction can reflect hemodynamics, infection or other nephrotoxins as well as calcineurin-inhibitor toxicity. Management balances toxicity against rejection protection; a falling GFR should prompt coordinated reassessment rather than an unsupported assumption that all immunosuppression should be stopped.
Apply it
A recipient develops hyperkalemia, tremor and worsening kidney function after a medication change. Review tacrolimus timing and exposure, interacting agents, perfusion and other renal causes, then coordinate a monitored adjustment with the transplant team.
Common pitfall: A concentration within a stated target range does not exclude every adverse effect. Conversely, renal dysfunction alone does not establish tacrolimus as the sole cause.
52.How does mycophenolate inhibit lymphocyte proliferation?
Mycophenolate mofetil is converted to mycophenolic acid, which inhibits inosine monophosphate dehydrogenase and reduces de novo guanosine nucleotide synthesis. This suppresses proliferative responses of T and B lymphocytes. Its mechanism differs from calcineurin inhibition and provides complementary immunosuppression. Important adverse effects include gastrointestinal toxicity and cytopenias, but diarrhea or leukopenia also requires consideration of infection and other medications. Mechanism helps predict toxicity without making every compatible symptom diagnostic of a drug reaction.
Apply it
A recipient taking mycophenolate develops persistent diarrhea and leukopenia. Evaluate infection, other drugs and mycophenolate toxicity together, using laboratory and clinical findings to guide a transplant-team plan rather than independently discontinuing protection against rejection.
Common pitfall: Mycophenolate does not inhibit calcineurin. Confusing the mechanisms can obscure why combination therapy is used and why its gastrointestinal and marrow effects require separate surveillance.
53.How do biopsy phenotype, clinical severity and timing determine treatment of cellular rejection and AMR?
Acute cellular rejection shows interstitial or perivascular inflammatory infiltrates with myocyte injury. ISHLT grades are 0R, none; 1R, mild with at most one focus of myocyte injury; 2R, moderate with at least two injury foci; and 3R, severe diffuse inflammation with multifocal injury. Antibody-mediated rejection (AMR) involves microvascular injury, including endothelial changes and intravascular macrophages, with immunopathologic findings such as capillary C4d deposition. pAMR 0 lacks histologic and immunopathologic evidence; pAMR 1 has either component alone; pAMR 2 has both; pAMR 3 denotes severe pathologic AMR. Asymptomatic 1R usually requires no rejection-specific treatment, although maintenance immunosuppression should be checked. Asymptomatic 2R ordinarily receives oral or intravenous corticosteroids. However, selected asymptomatic 2R episodes occurring more than 12 months after transplantation may be managed without a corticosteroid course by optimizing maintenance immunosuppression and arranging close clinical, echocardiographic and repeat-biopsy surveillance. Treat 3R with intravenous corticosteroids regardless of symptoms. Symptomatic cellular rejection requires intravenous corticosteroids regardless of biopsy grade; hemodynamic compromise or corticosteroid-resistant rejection warrants additional cytolytic therapy such as antithymocyte globulin. Clinically significant AMR may require corticosteroids, plasma exchange and IVIG, with additional antibody-directed therapy according to severity and response.
Apply it
An asymptomatic recipient 18 months after transplantation with incidental 2R, preserved ventricular function and no hemodynamic compromise may qualify for maintenance-regimen optimization without a steroid pulse when close follow-up and repeat biopsy are assured. The same biopsy grade with new ventricular dysfunction or heart-failure symptoms requires treatment. A 3R result requires treatment even when the recipient feels well.
Common pitfall: The late-2R exception requires active surveillance; it does not justify waiting for symptoms before reassessment. Do not apply it to symptomatic rejection or 3R. Donor-specific antibodies alone do not establish pathologic AMR, and their absence does not exclude it. Integrate biopsy phenotype, graft function, hemodynamics and time since transplantation.
54.Which isolated donor-specific antibody findings justify closer graft assessment?
New DSA warrants assessment of graft function and review of adherence and immunosuppressant exposure. Concerning features include persistence, a late rise, HLA-DQ specificity, complement-binding properties and continued detectability at higher serum dilutions. These characteristics increase concern even with preserved EF and can justify endomyocardial biopsy to look for otherwise unrecognized injury. Repeat antibody testing helps establish the trajectory, but assay fluorescence alone is not a universal treatment threshold. Treatment of isolated DSA with stable graft function and negative pathology remains uncertain; antibody detection alone does not establish clinical AMR.
Apply it
A recipient develops persistent, late-rising HLA-DQ DSA that binds complement and remains detectable after substantial dilution. Assess graft function and consider biopsy despite preserved EF; review exposure and adherence while evaluating for tissue injury.
Common pitfall: High-risk DSA features support investigation rather than automatic intensive treatment. Stable function with negative pathology leaves a management uncertainty that requires surveillance and individualized decisions.
2025 ISHLT Consensus Summary on Antibodies and Antibody-Mediated Rejection in Heart Transplantation
55.What coronary pattern characterizes cardiac allograft vasculopathy?
Cardiac allograft vasculopathy often produces diffuse, concentric narrowing involving long coronary segments and distal vessels, rather than only discrete focal plaques. This distribution can make conventional angiography underestimate disease when there is no clearly normal reference segment. The foundational ISHLT nomenclature integrates coronary anatomy and graft dysfunction into disease assessment. Recognizing the pattern supports appropriate surveillance interpretation, but the 2010 nomenclature document should not be treated as a current medication or revascularization protocol for every clinical presentation.
Apply it
A recipient's coronary study shows diffuse distal pruning and long smooth narrowing without a dominant focal stenosis. Consider allograft vasculopathy and interpret the anatomy with graft performance rather than concluding that absence of one severe focal lesion excludes important disease.
Common pitfall: Applying only a native-coronary focal-stenosis model can underestimate diffuse allograft disease. A comparatively preserved-looking segment may itself be abnormal and provide a misleading angiographic reference.
ISHLT Standardized Nomenclature for Cardiac Allograft Vasculopathy — 2010
56.Why do vaccination and malignancy prevention remain lifelong transplant priorities?
Maintenance immunosuppression increases susceptibility to infection and malignancy while potentially reducing vaccine responses. Live attenuated vaccines should be avoided during mycophenolate or tacrolimus treatment according to their labeling. Prevention also includes sun protection, attention to suspicious skin lesions and appropriate screening. Vaccination decisions require assessment of the specific product and immunosuppressive state; avoiding live vaccines does not mean abandoning all immunization. Counseling should connect infection prevention and cancer surveillance with the continuing consequences of chronic immune suppression.
Apply it
A stable recipient taking tacrolimus and mycophenolate asks about a live travel vaccine and a changing skin lesion. Review a suitable travel-prevention alternative and arrange lesion assessment, explaining why clinical stability does not remove immunosuppression-related risks.
Common pitfall: Years without rejection do not restore normal immune function during maintenance therapy. Conversely, the live-vaccine restriction should not be generalized to every vaccine product.
DailyMed: CellCept Prescribing Information, Version 50 · DailyMed: Tacrolimus Prescribing Information
57.How should pregnancy planning change mycophenolate management and contraception?
Mycophenolate increases pregnancy-loss and congenital-malformation risks. Patients who can become pregnant need acceptable contraception throughout treatment and for six weeks after stopping, unless practicing abstinence. Label-supported choices include an IUD alone or specified combinations of hormonal and barrier methods. Mycophenolate may reduce oral contraceptive effectiveness; an additional barrier method is recommended when oral contraceptives are used. Before conception, coordinate regimen substitution and assessment of graft stability and maternal risk with transplantation and maternal-fetal medicine specialists. The six-week contraception interval does not itself establish pregnancy suitability, and abrupt self-discontinuation exposes the graft to rejection.
Apply it
A recipient wishing to conceive takes mycophenolate and an oral contraceptive. Recommend an additional barrier method, arrange supervised regimen substitution and graft assessment, and maintain acceptable contraception for at least six weeks after the final mycophenolate dose.
Common pitfall: Contraception must continue after discontinuation, not merely during the treatment transition. Stable ventricular function alone neither establishes pregnancy readiness nor removes mycophenolate's fetal risk.
Pulmonary Hypertension5%
58.How do wedge pressure and PVR classify Group 2 pulmonary hypertension?
Pulmonary hypertension is defined hemodynamically by mean pulmonary artery pressure greater than 20 mmHg. A wedge pressure above 15 mmHg supports postcapillary physiology, commonly from left heart disease. Calculate PVR as mean pulmonary artery pressure minus wedge pressure, divided by cardiac output. PVR at most 2 Wood units identifies isolated postcapillary PH; a value above 2 identifies combined postcapillary and precapillary PH. Interpret measurements with volume status and clinical context because decompensation and treatment can alter classification.
Apply it
A patient with HF has mean pulmonary artery pressure 34 mmHg, wedge pressure 22 mmHg and cardiac output 4 L/min. PVR is 3 Wood units, identifying combined postcapillary and precapillary physiology in the appropriate clinical context.
Common pitfall: Elevated PVR does not convert a patient with elevated wedge pressure into isolated PAH. Pressure, flow and the underlying clinical cause must be interpreted together.
59.How are Group 1 PAH and Group 3 pulmonary hypertension distinguished?
Precapillary PH requires mean pulmonary artery pressure above 20 mmHg, wedge pressure at most 15 mmHg and PVR above 2 Wood units. These measurements establish physiology, not the clinical group. Group 1 PAH requires evaluation for associated conditions and exclusion of other explanations, while substantial lung disease or hypoxia supports Group 3. Pulmonary function testing, gas exchange and chest imaging help determine the dominant mechanism. The revised diagnostic thresholds alone do not establish eligibility for every targeted pulmonary vascular treatment.
Apply it
A patient has precapillary PH and extensive fibrotic lung disease with hypoxemia. Integrate pulmonary testing and imaging before assigning PAH, because the same catheterization pattern can occur in clinically different groups with different treatment implications.
Common pitfall: Normal wedge pressure does not make all PH Group 1. Lung disease, chronic thromboembolic obstruction and other mechanisms must be assessed before clinical classification.
60.Why is ventilation/perfusion imaging important when evaluating CTEPH?
Chronic thromboembolic pulmonary hypertension belongs to Group 4 and requires recognition of chronic pulmonary vascular obstruction. Ventilation/perfusion imaging is a key screening investigation in unexplained PH because mismatched perfusion defects can identify a thromboembolic pattern. A prior CT report without acute embolism does not reliably answer the chronic-obstruction question. Abnormal screening requires anatomical characterization and expert evaluation. A scan establishes a diagnostic direction rather than independently determining operability or the final treatment strategy.
Apply it
A patient has unexplained precapillary PH despite a previous CT report stating no acute pulmonary embolus. Obtain ventilation/perfusion imaging to assess chronic thromboembolic disease, rather than treating the prior acute-embolism interpretation as a complete Group 4 exclusion.
Common pitfall: Absence of a recognized prior embolic event does not exclude CTEPH. Mismatched perfusion defects also require further characterization rather than immediate assignment of a surgical plan.
What to focus on during revision
The following are CertMedbry study suggestions. Use the official outline to check the full scope of your examination.
- Use the official expanded CERT outline as the full syllabus; this guide selectively samples its four domains.
- Allocate study approximately 40% to Heart Failure, 30% to Mechanical Circulatory Support, 25% to Heart Transplantation and 5% to Pulmonary Hypertension.
- Within Heart Failure, emphasize HFrEF treatment and acute physiology while retaining HFpEF diagnosis, current treatment and etiologic discrimination.
- For temporary support, connect the failing chamber and oxygenation requirement to device capabilities, contraindications and complications.
- For durable support, distinguish inadequate filling from equipment failure and rehearse power, driveline and emergency assessment principles.
- For transplantation, integrate candidacy, pulmonary vascular load, donor compatibility, immunosuppression exposure and evidence of graft injury.
- Practise pressure-flow calculations with units and classify pulmonary hypertension using both wedge pressure and PVR.
- Apply health equity throughout clinical decisions by identifying cost, language, literacy, transport and caregiver barriers with specific remedies.
A practical preparation plan
1. Map the full CERT scope
Read the January 2026 blueprint and expanded outline. Mark each numbered topic as secure, developing or unreviewed, including etiologies and transplant-management topics beyond these 60 concepts.
2. Build a hemodynamic worksheet
For each case, record congestion, perfusion, right atrial pressure, pulmonary pressures, wedge pressure and cardiac output when available. Calculate PVR and identify which findings support the proposed mechanism.
3. Practise treatment boundaries
Review foundational HFrEF eligibility, ACE inhibitor washout, beta-blocker timing, renal and potassium monitoring, CRT selection and continued therapy after EF improvement. Pair each treatment with a contraindication or competing risk.
4. Trace support through the circulation
Draw the inlet and outlet of each support configuration. Explain what happens when RV delivery falls, aortic afterload rises, lung oxygenation remains poor or a cannulated limb loses perfusion.
5. Link transplant findings to evidence of injury
Separate antibody detection, donor specificity, drug exposure, graft dysfunction and tissue injury. Review how each changes the next investigation or management decision without assuming that any one result proves rejection.
6. Complete and explain the learning questions
Answer the 20 independent drills, then explain why every alternative is less appropriate using its option text. Track errors by official domain and by diagnosis, treatment, prognosis or mechanism; the small set does not predict examination performance.
7. Use recall to close remaining gaps
Review the flashcards with spaced recall, then return to the full outline for uncovered topics. Use the format FAQs and ABIM's current examination page to plan examination-day timing and breaks.
Use your sample score as a starting point
The free set contains 20 original practice questions. It is a small learning sample, not an official examination or a validated pass prediction. Review each explanation and its source before moving to another topic.
Start the free sampleOfficial sources and updates
- ABIM: Advanced Heart Failure and Transplant Cardiology Certification Policies
- Advanced Heart Failure and Transplant Cardiology Certification Examination Blueprint — January 2026
- Advanced Heart Failure and Transplant Cardiology Certification Examination Expanded Blueprint
- ABIM Expanded Blueprints
- 2022 AHA/ACC/HFSA Heart Failure Guideline Slide Set
- 2024 ACC Expert Consensus for Treatment of HFrEF: Key Points
- Management of HFpEF: 2026 ACC Expert Consensus Decision Pathway — Key Takeaways
- 2023 ACC Expert Consensus on Management of HFpEF: Key Points
- 2023 ACC Expert Consensus on Cardiac Amyloidosis: Key Points
- Getinge: The IABP Numbers Game
- Impella 2.5 Instructions for Use and Clinical Reference Manual
- ELSO Interim Guidelines for Venoarterial ECMO in Adult Cardiac Patients
- ACC: 2025 Clinical Guidance on Evaluation and Management of Cardiogenic Shock
- HeartMate 3 Left Ventricular Assist System Instructions for Use
- Hemodynamic Markers of Pulmonary Vasculopathy for Prediction of Early Right Heart Failure and Mortality After Heart Transplantation
- 2025 ISHLT Consensus Summary on Antibodies and Antibody-Mediated Rejection in Heart Transplantation
- DailyMed: Tacrolimus Prescribing Information
- ISHLT Standardized Nomenclature for Cardiac Allograft Vasculopathy — 2010
- DailyMed: CellCept Prescribing Information, Version 50
- Definition, Classification and Diagnosis of Pulmonary Hypertension — 2024 World Symposium Task Force Report
- 2022_guideline_ishlt_careofhtxrecipients.pdf
- 2026_consensusdocument_ishlt_graftdysfunctionafterhtx.pdf
- 215341s009lbl.pdf
- _pdf
- 2022_guideline_ishlt_careofhtxrecipients.pdf
- circulationE38288E3828A.pdf
- Modified Bicaval Technique in Orthotopic Heart Transplantation ― Comparison With Conventional Bicaval Technique ―
- ACC ECDP for Diagnosis and Management of Myocarditis: Key Points - American College of Cardiology
Confirm current eligibility, fees, scheduling and policies directly with the examination provider. CertMedbry is independent and is not endorsed by these organisations. How we handle content and corrections.